Vantage Data Points
Venture funding distribution – medtech and biopharma
For more on venture financing trends in biopharma and medtech see: Venture investing dips again for biopharma and Medtech VC and the billion-dollar era
Too much of a good thing?
For a more in-depth look at Merck's case see: Merck and the pitfalls of biopharma success
China's PD(L)-1 players
After Celgene’s return of tislelizumab rights Beigene will be looking for a new ex-China partner. The volume of work Beigene and others are already doing in China suggests the threat to US players of multiple low-cost, Asia-developed drugs.
Image can be enlarged by opening in new tab on Chrome or other browsers.
Externally sourced approvals fall for big companies
For a wider look at product strategy in US approvals and sales, see If you want blockbuster sales, buy them in, April 29, 2019.
First-quarter share price successes
For more on Q1 2019 share price performances see: Topsy turvy times for industry’s mid and small cap stocks in the first quarter and US big biotechs lag in the opening quarter of the year
Biopharma takeouts – development-stage deals
For further analyses on recent M&A deals see: Following the M&A money, by phase and therapy area, January 29, 2019.
